Di Lascio Gabriella, Prifti Edvin, Messai Elmi, Peris Adriano, Harmelin Guy, Xhaxho Roland, Fico Albana, Sani Guido, Bonacchi Massimo
1 Section of Cardiac Surgery, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
2 Division of Cardiac Surgery, University Hospital Center of Tirana, Tirana, Albania.
Perfusion. 2017 Mar;32(2):157-163. doi: 10.1177/0267659116670481. Epub 2016 Oct 7.
Status asthmaticus is a life-threatening condition characterized by progressive respiratory failure due to asthma that is unresponsive to standard therapeutic measures. We used extracorporeal membrane oxygenation (ECMO) to treat patients with near-fatal status asthamticus who did not respond to aggressive medical therapies and mechanical ventilation under controlled permissive hypercapnia.
Between January 2011 and October 2015, we treated 16 adult patients with status asthmaticus (8 women, 8 men, mean age: 50.5±10.6years) with veno-venous ECMO (13 patients) or veno-arterial (3 patients). Patients failed to respond to conventional therapies despite receiving the most aggressive therapies, including maximal medical treatments, mechanical ventilation under controlled permissive hypercapnia and general anesthetics.
Mean time spent on ECMO was 300±11.8 hours (range 36-384 hours). PaO, PaCO and pH showed significant improvement promptly after ECMO initiation p=0.014, 0.001 and <0.001, respectively, and such values remained significantly improved after ECMO, p=0.004 and 0.001 and <0.001, respectively. The mean time of ventilation after decannulation until extubation was 175±145.66 hours and the median time to intensive care unit discharge after decannulation was 234±110.30 hours. All 16 patients survived without neurological sequelae.
ECMO could provide adjunctive pulmonary support for intubated asthmatic patients who remain severely acidotic and hypercarbic despite aggressive conventional therapy. ECMO should be considered as an early treatment in patients with status asthmaticus whose gas exchange cannot be satisfactorily maintained by conventional therapy for providing adequate gas change and preventing lung injury from the ventilation.
哮喘持续状态是一种危及生命的疾病,其特征为哮喘导致进行性呼吸衰竭,且对标准治疗措施无反应。我们采用体外膜肺氧合(ECMO)治疗对积极的药物治疗和在控制性允许性高碳酸血症下进行机械通气均无反应的近乎致命的哮喘持续状态患者。
2011年1月至2015年10月期间,我们用静脉-静脉ECMO(13例患者)或静脉-动脉ECMO(3例患者)治疗了16例成年哮喘持续状态患者(8例女性,8例男性,平均年龄:50.5±10.6岁)。尽管接受了最积极的治疗,包括最大剂量的药物治疗、在控制性允许性高碳酸血症下进行机械通气及全身麻醉,但患者对传统治疗仍无反应。
ECMO平均使用时间为300±11.8小时(范围36 - 384小时)。开始ECMO后,动脉血氧分压(PaO)、动脉血二氧化碳分压(PaCO)和pH值迅速显著改善,p值分别为0.014、0.001和<0.001,且ECMO后这些值仍显著改善,p值分别为0.004、0.001和<0.001。脱管至拔管后的平均通气时间为175±145.66小时,脱管后至重症监护病房出院的中位时间为234±110.30小时。16例患者均存活,无神经后遗症。
对于尽管接受了积极的传统治疗仍严重酸中毒和高碳酸血症的插管哮喘患者,ECMO可提供辅助性肺支持。对于气体交换不能通过传统治疗得到满意维持的哮喘持续状态患者,应考虑将ECMO作为早期治疗手段,以提供足够的气体交换并防止通气造成的肺损伤。